3 Biotech Quick Picks to Invest $5,000 This Week
Building a balanced portfolio of healthcare stocks requires investing in safer and more mature companies as well as riskier upstarts to drive long-term growth. Between Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN), and Vir Biotechnology (NASDAQ: VIR), there's something here for every investor.
Image source: YCharts.
Gilead's stock has posted consistent growth this year as a result of its ambitious antiviral drug development program for COVID-19. With the preliminary publication of favorable clinical trial results for Gilead's remdesivir antiviral, the company cemented its earlier growth for the short term. On Thursday, Roche revealed that it was testing Gilead's remdesivir as part of a combination therapy for COVID-19, a move which will doubtlessly be followed by others in the coming weeks. Even if Gilead's remdesivir program doesn't show that it is effective for COVID-19, there's a good chance that at least one of the combination therapy collaborations will yield fruit, and Gilead will come out of the pandemic stronger as a result.
Source Fool.com
